Amgen's Repatha Cuts Cardiovascular Risk by 31% in High-Risk Patients

Key Facts

Amgen (NASDAQ: AMGN) announced positive results from its VESALIUS-CV clinical trial, demonstrating that its drug Repatha significantly reduces cardiovascular risks. The study found that Repatha (evolocumab) lowered the risk of major adverse cardiovascular events (MACE) by 31% in high-risk primary prevention patients. Notably, the treatment showed high efficacy in patients with diabetes who have no established history of atherosclerosis. This makes Repatha the only PCSK9 inhibitor to achieve such significant risk reduction in this specific patient subgroup. Analysts view these findings as a major long-term growth driver for Amgen, strengthening its competitive position in the biotechnology sector. The data supports earlier initiation of treatment for patients with elevated LDL-C levels to prevent initial cardiac events.